4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; Benitec; CRF; Roche; CFF; and AstraZeneca. The company was founded in 2013 and is headquartered in Emeryville, California.
IPO Year: 2020
Exchange: NASDAQ
Website: 4dmoleculartherapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/13/2025 | $40.00 → $15.00 | Outperform → Market Perform | BMO Capital Markets |
| 11/21/2024 | $8.00 | Underweight | Morgan Stanley |
| 9/23/2024 | Overweight → Neutral | Cantor Fitzgerald | |
| 4/15/2024 | $45.00 | Overweight | Barclays |
| 4/15/2024 | $459.00 | Overweight | Barclays |
| 2/7/2024 | $81.00 | Buy | Goldman |
| 10/26/2023 | $25.00 | Outperform | RBC Capital Mkts |
| 10/24/2023 | $32.00 | Overweight | Cantor Fitzgerald |
| 10/18/2023 | $24.00 | Market Perform → Outperform | Leerink Partners |
| 7/5/2023 | $30.00 | Buy | Chardan Capital Markets |
8-K - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
SCHEDULE 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)
S-8 - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
10-Q - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
8-K - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
DEFA14A - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
DEF 14A - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
EFFECT - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
POS AM - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
S-8 - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
EMERYVILLE, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in fireside chats at upcoming investor conferences in June. Members of the management team will also be available for one-on-one meetings. Jefferies Global Healthcare Conference Presentation Date:Wednesday, June 4, 2025Presentation Time:3:45 p.m. ETWebcast Link:Webcast Goldman Sachs Global Healthcare Conference Presentation Date:Wednesday,
EMERYVILLE, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on May 13, 2025, the compensation committee of the Company's board of directors granted eight new non-executive employees 31,800 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company's 2025 Employment Inducement Award Plan, which was approved by the Company's board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global Market f
Enrolled first patients in first 4D-150 Phase 3 clinical trial (4FRONT-1) in wet AMD, with over 50 clinical trial sites open to dateInitiation of second 4D-150 Phase 3 clinical trial (4FRONT-2) expected in Q3 2025, with topline data from both 4FRONT-1 and 4FRONT-2 expected in H2 2027RMAT designation received from FDA for 4D-150 in DME, adding to previous regulatory designations of RMAT and PRIME (EMA) for 4D-150 in wet AMD$458 million in cash, cash equivalents, and marketable securities as of March 31, 2025, expected to fund planned operations into 2028 EMERYVILLE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage
EMERYVILLE, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in fireside chats at upcoming investor conferences in May. Members of the management team will also be available for one-on-one meetings. BofA Securities 2025 Healthcare Conference Presentation Date:Wednesday, May 14, 2025Presentation Time:2:20 p.m. PTWebcast Link:Webcast RBC Capital Markets 2025 Global Healthcare Conference Presentatio
EMERYVILLE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the U.S. Food and Drug Administration (FDA) has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to 4D-150 for the treatment of diabetic macular edema (DME). "This milestone validates the potential of 4D-150 to address the significant unmet needs of patients with DME, a second large market retinal vascular disease indication after wet age-related
EMERYVILLE, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on April 8, 2025, the compensation committee of the Company's board of directors granted three new non-executive employees 16,500 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company's 2025 Employment Inducement Award Plan, which was approved by the Company's board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global Marke
EMERYVILLE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in a fireside chat at the upcoming RBC Capital Markets 2025 Ophthalmology Conference being held virtually on April 3-4, 2025. Members of the management team will also be available for one-on-one meetings. RBC Capital Markets 2025 Ophthalmology Conference Presentation Date:Thursday, April 3, 2025Presentation Time:9:15 a.m. ETWebcast Link:
EMERYVILLE, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the first patients have been enrolled across multiple sites in the 4FRONT-1 Phase 3 clinical trial evaluating 4D-150 for the treatment of wet age-related macular degeneration (wet AMD). "This is a historic moment for 4DMT as we become a Phase 3 company following our initiation of the 4FRONT-1 clinical trial," said David Kirn, M.D., Co-founder and Chief Executive Of
Presented positive interim data through 52 weeks and beyond for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patient populations and continued favorable tolerability Announced positive interim 32-week data for 4D-150 in DME from Part 1 of SPECTRA clinical trial and alignment with FDA for a single Phase 3 trial being acceptable for the basis of BLA submission for 4D-150 in DME when combined with data generated from 4FRONT Phase 3 trials in wet AMD4FRONT Phase 3 program in wet AMD on track with initiation of 4FRONT-1 expected in March 2025 and 4FRONT-2 in Q3 2025, with topline data from both studies expected in 2H 20
EMERYVILLE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading clinical-stage company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in fireside chats at upcoming investor conferences in March. Members of the management team will also be available for one-on-one meetings. Leerink's Global Biopharma Conference 2025 Presentation Date: Tuesday, March 11, 2025Presentation Time: 10:00 a.m. ETWebcast Link: Webcast Barclays Global Healthcare Conference 2025 Presentation Date: Wednesday, March 12, 2025Presentation Time: 10:00 a.m. ETWebc